|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM207475083 |
| 003 |
DE-627 |
| 005 |
20250212160651.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2011 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2011.03.016
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n0691.xml
|
| 035 |
|
|
|a (DE-627)NLM207475083
|
| 035 |
|
|
|a (NLM)21493160
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Hogan, Andrew E
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide
|
| 264 |
|
1 |
|c 2011
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 03.10.2011
|
| 500 |
|
|
|a Date Revised 25.07.2011
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2011 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Activation of CD1d-restricted invariant NKT (iNKT) cells with the glycolipid α-galactosylceramide (α-GalCer) confers protection against disease in murine models, however, clinical trials in humans have had limited impact. We synthesized a novel thioglycoside analogue of α-GalCer, denoted α-S-GalCer, and tested its efficacy for stimulating human iNKT cells in vitro. α-S-GalCer stimulated cytokine release by iNKT cells in a CD1d-dependent manner and primed CD1d(+) target cells for lysis. α-S-GalCer-stimulated iNKT cells induced maturation of monocyte-derived dendritic cells into antigen-presenting cells that released IL-12 and small amounts of IL-10. The nature and potency of α-S-GalCer and α-GalCer in human iNKT cell activation were similar. However, in contrast to α-GalCer, α-S-GalCer did not activate murine iNKT cells in vivo. Because of its enhanced stability in biological systems, α-S-GalCer may be superior to α-GalCer as a parent compound for developing adjuvant therapies for humans
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Antigens, CD1d
|2 NLM
|
| 650 |
|
7 |
|a Galactosylceramides
|2 NLM
|
| 650 |
|
7 |
|a Thiogalactosides
|2 NLM
|
| 650 |
|
7 |
|a Thioglycosides
|2 NLM
|
| 650 |
|
7 |
|a alpha-S-galactosylceramide
|2 NLM
|
| 650 |
|
7 |
|a alpha-galactosylceramide
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-10
|2 NLM
|
| 650 |
|
7 |
|a 130068-27-8
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-12
|2 NLM
|
| 650 |
|
7 |
|a 187348-17-0
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-4
|2 NLM
|
| 650 |
|
7 |
|a 207137-56-2
|2 NLM
|
| 650 |
|
7 |
|a Interferon-gamma
|2 NLM
|
| 650 |
|
7 |
|a 82115-62-6
|2 NLM
|
| 700 |
1 |
|
|a O'Reilly, Vincent
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Dunne, Margaret R
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Dere, Ravindra T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zeng, Shijuan G
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a O'Brien, Cashel
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Amu, Sylvie
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Fallon, Padraic G
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Exley, Mark A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a O'Farrelly, Cliona
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhu, Xiangming
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Doherty, Derek G
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 140(2011), 2 vom: 15. Aug., Seite 196-207
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnas
|
| 773 |
1 |
8 |
|g volume:140
|g year:2011
|g number:2
|g day:15
|g month:08
|g pages:196-207
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2011.03.016
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 140
|j 2011
|e 2
|b 15
|c 08
|h 196-207
|